Elite in Primary Lateral Sclerosis

Albert C. Ludolph

Albert Einstein Allee 11, 
Ulm, BW, DE 
Elite in Primary Lateral Sclerosis
Albert Einstein Allee 11, 
Ulm, BW, DE 
OverviewLocationsClinical Research

Overview

Albert Ludolph practices in Ulm, Germany. Mr. Ludolph is rated as an Elite expert by MediFind in the treatment of Primary Lateral Sclerosis. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Gastrostomy, and Thrombectomy.

His clinical research consists of co-authoring 653 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 412 articles and participated in 4 clinical trials in the study of Primary Lateral Sclerosis.

Gender
Male

Locations

Albert Einstein Allee 11, Ulm, BW 89081, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic Lateral Sclerosis (sALS)
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic Lateral Sclerosis (sALS)
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drug: AP-101
Study Phase: Phase 2
Genetic Screening of an At-risk Population for Hereditary TransthyRetin-related AMyloidosis and Longitudinal Monitoring of TTR Positive Subjects- A Multicenter Epidemiological Longitudinal Protocol
Genetic Screening of an At-risk Population for Hereditary TransthyRetin-related AMyloidosis and Longitudinal Monitoring of TTR Positive Subjects- A Multicenter Epidemiological Longitudinal Protocol
Enrollment Status: Completed
Publish Date: June 29, 2025
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Enrollment Status: Terminated
Publish Date: August 24, 2023
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 3
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Drug
Study Phase: Phase 3
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Unknown
Publish Date: July 10, 2023
Intervention Type: Drug
Study Drug: Tauroursodexycholic Acid
Study Phase: Phase 3
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study
Enrollment Status: Completed
Publish Date: April 12, 2021
Intervention Type: Other
Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome
Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome
Enrollment Status: Completed
Publish Date: September 11, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 6 Less Clinical Trials

650 Total Publications

Progress in ALS research 2025.
Progress in ALS research 2025.
Journal: Current opinion in neurology
Published: September 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ludolph's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 18 Advanced Conditions
View All 62 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile